Background
Since
December 2019, the newly emerged SARS-CoV-2 virus continues to infect
humans and many people died from severe Covid-19 during the last 2 years
worldwide. Different approaches are being used for treatment of this
infection and its consequences, but limited results have been achieved
and new therapeutics are still needed. One of the most interesting
biotherapeutics in this era are Nanobodies which have shown very
promising results in recent researches.
Scope of review
Here,
we have reviewed the potentials of Nanobodies in Covid-19 treatment. We
have also discussed the properties of these biotherapeutics that make
them very suitable for pulmonary drug delivery, which seems to be very
important route of administration in this disease.
Major conclusion
Nanobodies
with their special biological and biophysical characteristics and their
resistance against harsh manufacturing condition, can be considered as
promising, targeted biotherapeutics which can be administered by
pulmonary delivery pharmaceutical systems against Covid-19.
General significance
Covid-19
has become a global problem during the last two years and with emerging
mutant strains, prophylactic and therapeutic approaches are still
highly needed. Nanobodies with their specific properties can be
considered as valuable and promising candidates in Covid-19 therapy.